EXACT Therapeutics announces grant of key patent covering non-invasive delivery of pharmaceuticals to the brain

14 May 2025 08:35 CEST

Oslo, Norway, 14 May, 2025 - EXACT Therapeutics AS (Euronext Growth:EXTX), a
clinical stage precision medicine company utilizing the power of ultrasound to
enable targeted drug delivery in oncology, has been informed that the
Intellectual Property Office in the United Kingdom has granted EXACT’s United
Kingdom Patent no. 2104590.1 entitled “Treatment of the central nervous system”.

The granted patent covers EXACT’s proprietary Acoustic Cluster Therapy (ACT®)
for the treatment of diseases of the central nervous system (CNS), including the
brain.

Per Walday, CEO of EXACT, comments, ”We are thrilled to announce the granting of
this patent in its first territory, marking an important milestone for the
development of ACT. The blood-brain barrier has long posed a major challenge to
delivering treatments to the brain. Our ACT technology may open exciting new
possibilities by enabling access to larger brain areas and paving the way for
more effective therapies. One of the most compelling applications is in
glioblastoma – the most common form of brain cancer – where we recently reported
encouraging non-clinical results.”

About Exact Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics’
shares are traded on Euronext Growth Oslo (EXTX).

www.exact-tx.com


For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

More information:
Access the news on Oslo Bors NewsWeb site